Table 2.

Selected active clinical trials of immunotherapy and chemoradiation for LS-SCLC.

ClinicalTrials.gov Trial ID	Intervention	Primary end point	Study status	Study design
NCT03811002	CRT (EP) ± concurrent atezolizumab	PFS, OS	Active, Recruiting	Phase II/III
NCT02402920	CRT (EP) + concurrent pembrolizumab	Pembrolizumab maximum tolerated dose	Active, Recruiting	Phase I
NCT04189094	CRT (EP) ± concurrent sintilimab	PFS at 2 years	Active, not yet recruiting	Phase II
NCT03540420 (ACHILES)	CRT (EP) ± post-treatment atezolizumab	OS at 2 years	Active, Recruiting	Phase II
NCT03585998	CRT (EP) + concurrent and consolidation durvalumab	PFS	Active, Recruiting	Phase II
NCT03703297 (ADRIATIC)	Post-CRT (EP) durvalumab vs. durvalumab + tremelimumab vs. placebo	PFS, OS	Active, Recruiting	Phase III

CRT, chemoradiotherapy; EP, etoposide-cisplatin; PFS, progression-free survival; OS, overall survival.